The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.

NAD(P)H quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoenzyme that catalyzes two-electron reduction of quinones to hydroquinones utilizing NAD(P)H as an electron donor. NQO1 binds and stabilizes several short-lived proteins including the tumor suppressors p53 and p73 and the enzyme ornithine decarboxylase (ODC). Dicoumarol is a widely used potent competitive inhibitor of NQO1 enzymatic activity, which competes with NAD(P)H for binding to NQO1. Dicoumarol also disrupts the binding of NQO1 to p53, p73, and ODC and induces their ubiquitin-independent proteasomal degradation. We report here the crystal structure of human NQO1 in complex with dicoumarol at 2.75 A resolution. We have identified the interactions of dicoumarol with the different residues of NQO1 and the conformational changes imposed upon dicoumarol binding. The most prominent conformational changes that occur in the presence of dicoumarol involve Tyr 128 and Phe 232 that are present on the surface of the NQO1 catalytic pocket. On the basis of the comparison of the NQO1 structure in complex with different NQO1 inhibitors and our previous analysis of NQO1 mutants, we propose that the specific conformation of Tyr 128 and Phe 232 is important for NQO1 interaction with p53 and other client proteins.

[1]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .

[2]  Y. Shaul,et al.  p53 Proteasomal Degradation: Poly-Ubiquitination is Not the Whole Story , 2005, Cell cycle.

[3]  J. Lotem,et al.  Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Y. Shaul,et al.  20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. , 2005, Molecular cell.

[5]  Y. Shaul,et al.  A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. , 2005, Genes & development.

[6]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[7]  J. Lotem,et al.  p53-dependent apoptosis and NAD(P)H:quinone oxidoreductase 1. , 2004, Methods in enzymology.

[8]  J. Lotem,et al.  p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  David Siegel,et al.  Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* , 2003, The Journal of Biological Chemistry.

[10]  J. Lotem,et al.  Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Amzel,et al.  Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. , 2001, Biochemistry.

[13]  J. Lotem,et al.  Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Jaiswal,et al.  Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. , 2000, Biochemical pharmacology.

[15]  L. Amzel,et al.  Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Siegel,et al.  NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity* , 2000, The Journal of Biological Chemistry.

[17]  D. Siegel,et al.  NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. , 2000, The Journal of biological chemistry.

[18]  C. S. Yang,et al.  Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. , 1999, Molecular pharmacology.

[19]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[20]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[21]  L. Amzel,et al.  The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[23]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[24]  S. Chen,et al.  Inhibition of NAD(P)H:quinone acceptor oxidoreductase by flavones: a structure-activity study. , 1993, Archives of biochemistry and biophysics.

[25]  A. Y. Lu,et al.  Identification of a glycine-rich sequence as an NAD(P)H-binding site and tyrosine 128 as a dicumarol-binding site in rat liver NAD(P)H:quinone oxidoreductase by site-directed mutagenesis. , 1992, The Journal of biological chemistry.

[26]  P. Talalay,et al.  Inhibition of NAD(P)H:(quinone-acceptor) oxidoreductase by cibacron blue and related anthraquinone dyes: a structure-activity study. , 1992, Biochemistry.

[27]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[28]  D. Ross,et al.  Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. , 1990, Cancer research.

[29]  E. Cadenas,et al.  [30] DT-diaphorase : purification, properties, and function , 1990 .

[30]  K. Hayashi,et al.  Properties and reaction mechanism of DT diaphorase from rat liver. , 1974, The Journal of biological chemistry.

[31]  W. Wosilait,et al.  Comparative study of the binding of coumarin anticoagulants and serum albumins. , 1971, Biochemical pharmacology.